Oncology Clinic, Clinical Center University of Sarajevo, Bosnia and Herzegovina.
Bosn J Basic Med Sci. 2011 Nov;11(4):223-7. doi: 10.17305/bjbms.2011.2551.
High grade prostatic intraepithelial neoplasia (HGPIN) is widely regarded as the precancerous. The aim of this study was to determine PSA related parameters in patients with initial PSA values 2-10 ng/mL and diagnosis of HGPIN without finding carcinoma at the time of their first needle biopsy. Study groups consisted of 100 men who were diagnosed HGPIN, 84 with cancer and 183 with benign hyperplasia on first biopsy of prostate. Total PSA and free PSA were measured and ratio free/total PSA and PSA density calculated. Mean values of these parameters were compared, and receiver operating characteristic curves were used for comparison of PSA related parameters to discriminate groups of patients.Total PSA, free PSA level and PSA density in patients with HGPIN (6.388 ng/mL) did not differ significantly compared to prostate carcinoma (6.976 ng/mL) or benign prostatic hyperplasia (6.07 ng/mL) patients. Patients with HGPIN had significantly higher ratio free/total PSA than those with prostate carcinoma (0.168 vs 0.133), but significantly lower than patients with benign prostatic hyperplasia (0.168 vs 0.185). Ratio of free/total PSA significantly discriminate HGPIN from prostate carcinoma with sensitivity 84.52 and specify 45.00 at cut-off point of ≤ 0.18. Values of PSA, free PSA and ratio free/total PSA in cases of HGPIN appear to be intermediate between prostate cancer and normal levels. Ratio of free/total PSA may help in decision to repeat biopsies in the presence of HGPIN on biopsy, without concomitant prostate cancer, in patients suitable for curative treatment, with normal digito-rectal examination and trans-rectal sonography.
高级前列腺上皮内瘤变(HGPIN)被广泛认为是癌前病变。本研究旨在确定初始 PSA 值为 2-10ng/ml 且首次活检时未发现癌但诊断为 HGPIN 的患者的 PSA 相关参数。研究组包括 100 名被诊断为 HGPIN 的男性,84 名患有癌症,183 名患有良性前列腺增生。测量总 PSA 和游离 PSA,并计算游离/总 PSA 比值和 PSA 密度。比较这些参数的平均值,并使用受试者工作特征曲线比较 PSA 相关参数以区分患者组。与前列腺癌(6.976ng/ml)或良性前列腺增生(6.07ng/ml)患者相比,HGPIN 患者的总 PSA、游离 PSA 水平和 PSA 密度(6.388ng/ml)无显著差异。HGPIN 患者的游离/总 PSA 比值显著高于前列腺癌患者(0.168 比 0.133),但显著低于良性前列腺增生患者(0.168 比 0.185)。游离/总 PSA 比值可显著区分 HGPIN 与前列腺癌,其灵敏度为 84.52%,特异性为 45.00%,截止点为≤0.18。HGPIN 患者的 PSA、游离 PSA 和游离/总 PSA 比值似乎介于前列腺癌和正常水平之间。游离/总 PSA 比值可能有助于在存在 HGPIN 但无前列腺癌的情况下,对适合根治性治疗、数字直肠检查和经直肠超声正常的患者重复活检做出决策。